Merrimack Pharmaceuticals to Present Preclinical Data at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

        Print
| Source: Merrimack Pharmaceuticals

CAMBRIDGE, Mass., Oct. 15, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present preclinical research on two novel potential cancer therapies, MM-398 and MM-141, and an innovative platform for biomarker analysis at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place on October 19-23, 2013 at the Hynes Convention Center in Boston, Massachusetts. Presentations will include preclinical studies of MM-398, a nanolipsomal encapsulated form of irinotecan, and MM-141, a bispecific antibody co-targeting IGF-1R and ErbB3, and their activity in tumor models. Data will be shared in three poster sessions.

Poster Sessions

  • Session Title: Novel Assay Technology 1
    A205: Development and application of a platform for analysis of protein biomarkers in clinical biopsies of limited quantity
    Sunday, October 20, 2013, 12:30 PM – 7:30 PM
    Exhibit Hall C-D
     
  • Session Title: Tumor Microenvironment
    AC293: Irinotecan sucrosofate liposome injection, MM-398, demonstrates superior activity and control of hypoxia as measured through longitudinal imaging using [18F]FAZA PET compared to free irinotecan in a colon adenocarcinoma xenograft model
    Tuesday, October 22, 2013, 12:30 PM – 7:30 PM
    Exhibit Hall C-D
     
  • Session Title: Monoclonal Antibodies
    C169: MM-141, a bispecific antibody inhibitor of PI3K/AKT/mTOR, attenuates tumor growth and potentiates everolimus in mouse models of anti-hormone therapy-resistant ER/PR+ breast cancer
    Tuesday, October 22, 2013, 12:30 PM – 7:30 PM
    Exhibit Hall C-D

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six oncology therapeutics in clinical development. For more information, please visit Merrimack's website at www.merrimackpharma.com.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

Media Contacts:
Debbie Tseng, Merrimack
617-441-7659


Heather Gitlitz, Spectrum
202-955-6222